Clinical Report: Musings from The Power List: Michael May

Overview

Michael May discusses the advancements and challenges in cell and gene therapy, highlighting the progress in reprogramming induced pluripotent stem cells and the ongoing debate between autologous and allogeneic therapies.

Background

The field of cell and gene therapy is rapidly evolving, with significant challenges such as funding and market adoption remaining critical barriers to widespread implementation.

Data Highlights

No numerical or trial data was provided in the source material.

Key Findings

• Access to capital is a significant bottleneck in the cell and gene therapy sector.
• Demonstrating durable commercial success is crucial for attracting investors back to the field.
• Reprogramming of induced pluripotent stem cells (iPSCs) is advancing, enabling better safety and manufacturability.
• The allogeneic paradigm is essential for achieving cost-effective mass adoption of therapies.
• Clinical efficacy must be demonstrated quickly to meet commercial expectations.

Clinical Implications

Continuous evaluation of therapeutic headroom is necessary to align product development with market needs.

Conclusion

The insights shared by Michael May highlight the ongoing challenges and advancements in the cell and gene therapy landscape.

Related Resources & Content

1. The Emotive List?, The Analytical Scientist, 2015 -- The Emotive List?
2. 10 Lessons from The Power List (Part 1), The Analytical Scientist, 2024 -- 10 Lessons from The Power List (Part 1)
3. The Power of the List, The Medicine Maker, 2015 -- The Power of the List
4. Chemistry, Manufacturing, and Controls Flexibilities for Developing Human Cellular and Gene Therapy Products for a Biologics License Application | FDA, FDA, 2026 -- Chemistry, Manufacturing, and Controls Flexibilities
5. Exa-cel in Children with Transfusion-Dependent β-Thalassemia or Sickle Cell Disease | New England Journal of Medicine, NEJM, 2026 -- Exa-cel in Children with Transfusion-Dependent β-Thalassemia or Sickle Cell Disease
6. the medicine maker — And for 2020...
7. Chemistry, Manufacturing, and Controls Flexibilities for Developing Human Cellular and Gene Therapy Products for a Biologics License Application | FDA
8. Exa-cel in Children with Transfusion-Dependent β-Thalassemia or Sickle Cell Disease | New England Journal of Medicine
9. Frontiers | Editorial: Potency assays for use in manufacturing cellular immunotherapies